LY2835219 free base - CAS# 1231929-97-7 size:2mg solid BETP was used at 5-20

BETP was used at 5-20 µM in vitro and cellular assays

RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo

Smiles: CN(C)C1C=CC(=CC=1)C1=CC(=CC=C1)NC(=O)N(C)C

and it is a powerful inhibitor of kinases other than CK2

administration is less than 10 min

LY2835219 free base - CAS# 1231929-97-7 size:2mg solid BETP was used at 5-20LY2835219 free base, CAS No. 1231929 97 7, is orally available cyclin dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK mediated